Summary:
Symbiotec Pharmalab IPO subscription reached 1.85 times on Day 2, driven by strong NII, retail and employee participation. QIB subscription remained at 0.54 times, leaving institutional demand as the key factor to watch on the final bidding day. The ₹1,757 crore IPO closes on August 27, 2026, with shares priced between ₹938 and ₹988. Investors can check category-wise subscription data through NSE, BSE or their broker platform. The company operates across pharmaceutical APIs, biotechnology and specialty products, serving domestic and international markets.
Symbiotec Pharmalab, the Indore-based pharmaceutical and biotechnology company, continued its ₹1,757 crore mainboard IPO into Day 2, with subscription building meaningfully from the muted opening session. As of the update, overall subscription crossed the full mark to reach 1.85 times.
IPO Details
| Detail | Information |
|---|---|
| Issue Size | ₹1,757 crore (fresh issue ₹150 crore + OFS ₹1,607 crore) |
| Price Band | ₹938–₹988 per share |
| Lot Size | 15 shares |
| Minimum Investment (Retail) | ₹14,820 |
| Face Value | ₹2 per share |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Registrar | MUFG Intime India Pvt Ltd |
| Book-Running Lead Managers | JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, Nomura Financial Advisory |
Category-wise Breakdown on Day 2
| Category | Shares Offered/Reserved | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutional Buyers (QIBs) | 37,39,872 | 20,32,740 | 0.54 |
| — Foreign Institutional Investors | — | 2,90,895 | — |
| — Domestic FIs/Banks/Insurance | — | 210 | — |
| — Mutual Funds | — | — | — |
| — Others | — | 17,41,635 | — |
| Non Institutional Investors | 28,04,904 | 83,98,485 | 2.99 |
| — NII (bids above ₹10 lakh) | 18,69,936 | 45,89,685 | 2.45 |
| — NII (bids ₹2–10 lakh) | 9,34,968 | 38,08,800 | 4.07 |
| Retail Individual Investors (RIIs) | 65,44,776 | 1,37,35,455 | 2.10 |
| — Cut-off | — | 1,16,11,185 | — |
| — Price bids | — | 21,24,270 | — |
| Employees | 35,377 | 1,06,335 | 3.01 |
| — Cut-off | — | 91,305 | — |
| — Price bids | — | 15,030 | — |
| Total | 1,31,24,929 | 2,42,73,015 | 1.85 |
Data as of the Day 2 update, sourced from NSE Consolidated Bid Details (nseindia.com).
Symbiotec Pharmalab IPO - Day 2 Subscription Status
As of the update on Day 2, the issue received bids for 2,42,73,015 shares against 1,31,24,929 shares on offer, taking overall subscription to 1.85 times. Employees led the demand at 3.01 times, followed by Non-Institutional Investors at 2.99 times and Retail Individual Investors at 2.10 times, while Qualified Institutional Buyers stayed below the full-subscription mark at 0.54 times.
What Day 2 Numbers Indicate
Subscription crossing 1.85 times overall on Day 2 — up sharply from 0.80 times at the end of Day 1 — shows meaningful pickup in NII and retail participation, even as QIB bidding remains comparatively muted. Within the NII category, the ₹2–10 lakh bracket (4.07x) significantly outpaced the above-₹10-lakh bracket (2.45x), pointing to smaller HNIs leading the charge over larger applicants at this stage. With QIB bidding still below 1x, institutional demand — which typically surges on the final day of mainboard issues — will be the key factor determining the issue's overall subscription level by close on August 27.
Symbiotec Pharmalab IPO - Timetable
| Event | Date |
|---|---|
| Anchor Bid Date | August 21, 2026 |
| IPO Open Date | August 24, 2026 |
| IPO Close Date | August 27, 2026 |
| Allotment Finalisation | August 28, 2026 |
| Refund/Demat Credit | August 31, 2026 |
| Listing Date | September 1, 2026 |
| Listing Exchanges | BSE, NSE |
Should You Apply for Symbiotec Pharmalab IPO?
Incorporated in 2002 and headquartered in Indore, Symbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology, and complex injectables. The company's business spans corticosteroid and steroidal-hormone active pharmaceutical ingredients, along with nutritional ingredients and specialty products, serving both domestic and international regulated and emerging markets. Revenue grew 15% year-on-year to ₹872.26 crore in FY26, with profit after tax rising 14% to ₹109.90 crore.
Investors considering the issue should weigh the company's specialised API capabilities, steady revenue and profit growth, and exposure to regulated international markets against risks typical of the pharmaceutical API business, such as regulatory compliance requirements across geographies and pricing pressure in commoditised segments. As with any IPO, the decision should be based on individual risk appetite, investment horizon, and a review of the RHP rather than subscription numbers alone.
How to Apply for Symbiotec Pharmalab IPO
Investors can apply for the Symbiotec Pharmalab IPO through ASBA via their bank's net banking portal, via UPI-based ASBA through their stock broker's trading app, or offline by submitting a physical ASBA form through their broker. The minimum lot size is 15 shares, requiring a minimum investment of approximately ₹14,820 at the upper price band.
How to Check Symbiotec Pharmalab IPO Subscription Status
How to check Symbiotec Pharmalab IPO Subscription Status on NSE website
- Visit the NSE IPO issue information page (nseindia.com).
- Search for "Symbiotec Pharmalab" or enter the symbol SYMBIOTEC.
- Select "Consolidated Bid Details" from the dropdown to view category-wise subscription data.
- The page refreshes periodically to show live bidding figures during market hours.
How to check Symbiotec Pharmalab IPO Subscription Status on BSE website
- Visit the BSE IPO page (bseindia.com).
- Navigate to the "Active IPO" or "IPO Bidding" section.
- Select "Symbiotec Pharmalab Limited" from the list of active issues.
- View category-wise and overall subscription figures, updated through the bidding window.
How to check Symbiotec Pharmalab IPO Subscription Status on Ventura?
Ventura clients can track real-time subscription status for the Symbiotec Pharmalab IPO directly within the IPO section of the Ventura app or web platform, alongside category-wise bid data and allotment updates — without needing to switch between exchange websites.
IPO Subscription History
Previous Day Subscription
The issue opened on a subdued note on Day 1, subscribed 0.80 times overall, with Employees leading at 1.52 times and QIBs trailing at just 0.35 times, before demand picked up meaningfully going into Day 2.
Conclusion
Symbiotec Pharmalab's IPO gathered pace on Day 2, with overall subscription crossing 1.85 times on the back of stronger NII, retail, and employee demand. With two more days of bidding ahead until the issue closes on August 27, institutional participation will be the key factor to watch, as QIB bidding typically surges sharply in the final session of mainboard issues.
